CLASS ACTION UPDATE for AMGN, UNFI and RAD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / April 18, 2023 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

AMGN Shareholders Click Here: https://zlk.com/pslra-1/amgen-class-action-loss-submission-form?prid=38374&wire=1
UNFI Shareholders Click Here: https://zlk.com/pslra-1/united-natural-foods-inc-lawsuit-submission-form?prid=38374&wire=1
RAD Shareholders Click Here: https://zlk.com/pslra-1/rite-aid-lawsuit-submission-form?prid=38374&wire=1

* ADDITIONAL INFORMATION BELOW *

Amgen Inc. (NASDAQ:AMGN)

This lawsuit is on behalf of all persons who purchased or otherwise acquired Amgen common stock between July 29, 2020 and April 27, 2022, inclusive.
Lead Plaintiff Deadline : May 12, 2023
TO LEARN MORE, VISIT: https://zlk.com/pslra-1/amgen-class-action-loss-submission-form?prid=38374&wire=1

According to the filed complaint, (a) the U.S. government claimed Amgen owed more than $3 billion in back taxes for tax years 2010, 2011, and 2012; (b) the U.S. government claimed Amgen owed more than $5 billion in back taxes for tax years 2013, 2014, and 2015; (c) the U.S. government would likely claim Amgen owed materially more to the U.S. government than investors had been led to believe for subsequent tax years for which the Company had used the same profit allocation treatment between its U.S. and Puerto Rico operations; (d) Amgen had not taken sufficient accruals to account for its outstanding tax liabilities; (e) Amgen had failed to comply with Accounting Standards Codification Topic 450 and other rules and regulations regarding the preparation of its periodic filings with the U.S. Securities and Exchange Commission; and (f) Amgen's refusal to pay taxes claimed by the U.S. government exposed the Company to a substantial risk of severe financial penalties imposed by the Internal Revenue Service.

United Natural Foods, Inc. (NYSE:UNFI)

UNFI Lawsuit on behalf of: investors who purchased March 10, 2021 - March 7, 2023
Lead Plaintiff Deadline : May 19, 2023
TO LEARN MORE, VISIT: https://zlk.com/pslra-1/united-natural-foods-inc-lawsuit-submission-form?prid=38374&wire=1

According to the filed complaint, during the class period, United Natural Foods, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) despite its cost-saving Value Path initiative, United Natural Foods had not invested in improving its data management and related infrastructure; (2) as a result, the Company could not respond adequately to cost changes, such as inflationary pressure; (3) as a result, the Company could not appreciate the benefits of procurement gains and inventory gains achieved during fiscal 2022; (4) as a result of the foregoing, the Company's profitability would be materially adversely impacted; and (5) as a result of the foregoing, defendant's positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Rite Aid Corporation (NYSE:RAD)

RAD Lawsuit on behalf of: investors who purchased April 26, 2018 - March 13, 2023
Lead Plaintiff Deadline : May 19, 2023
TO LEARN MORE, VISIT: https://zlk.com/pslra-1/rite-aid-lawsuit-submission-form?prid=38374&wire=1

According to the filed complaint, during the class period, Rite Aid Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) until at least June 2019, Rite Aid filled at least hundreds of thousands of unlawful prescriptions for controlled substances that lacked a legitimate medical purpose, including for potentially lethal opioids such as oxycodone and fentanyl; (2) Rite Aid pharmacists filled these prescriptions despite clear "red flags" that indicated that the prescriptions were unlawful; (3) Rite Aid ignored evidence that its stores were dispensing unlawful prescriptions, and intentionally deleted internal notes about suspicious prescribers written by concerned pharmacists; (4) by knowingly filling unlawful prescriptions for controlled substances, Rite Aid violated the Controlled Substances Act and, where Rite Aid sought reimbursement from federal healthcare programs, also violated the False Claims Act; (5) as a result, it was at risk of prosecution by federal authorities such as the United States Department of Justice; and (6) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 4th Floor Suite #427
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ACCESSWIRE

News network reaching more than 1,500 media outlets in 98 countries. The newest, fastest-growing and most disruptive newswire available today.